“I agree with the Fda and the CDC, it must be selective and not mass”
Genoa – On the day Pfizer announces that it has “updated” its vaccine against the fearful Delta variant – reported for the first time in India, more contagious than the others and destined to become dominant – the theme of the third booster of the vaccine. As the infectious disease specialist pointed out Matteo Bassetti, head of infectious diseases at the San Martino hospital, taking up the note of two American bodies (il Fda, the US drug authority, and the Centers for Disease Control and Prevention) who responded to Pfizer / BioNTech’s announcement that they would seek authorization for a third dose of the vaccine to give “even greater protection,” coverage a two-dose course is already “enough” to reduce hospitalizations and deaths.
The clarification of the Fda and the CDC is clear: people fully vaccinated against Covid-19 do not need a third dose.
“I am not in favor of the third dose – says Bassetti – We must think that two doses still protect us against serious illness and against the event of death which is the reason why we are pushing with vaccinations. The third dose is a booster that I believe will be done in 2022 and it is welcome that it is also against variants. But taking the third dose today means protecting only against infections and we know well that this is not the goal. Instead, the aim is to reduce deaths and hospitalizations “.
“To us today, but also in October, the infections should not matter, but the number of people hospitalized in hospital or who get severe forms of pneumonia and because of this two doses are sufficient. I agree with Fda and Cdc: the third dose must be selective, addressed to a person perhaps because he is fragile or a problematic subject. The administration of the third dose therefore “it must not be the subject of a mass campaign“.
Iss: current vaccination coverage protects 100% from the most serious effects of Covid
The Istituto Superiore di Sanità has recently published a study in line with what was declared by the American drug authority on the efficacy of vaccines: if the two planned doses are completed, the drug is approximately 80% effective in protecting against infection and up to 100% protection against the most serious effects of the disease, for all age groups.
This is indicated by the data processed by the National Institute of Health from the National Vaccines Registry and the integrated surveillance of cases of Sars-CoV-2 virus infection relating to the period between 21 June and 4 July.
In the elaboration, the vaccination status of infected, hospitalized and deceased from Sars-Cov-2 was examined, and vaccination efficacy was calculated for four age groups, 12-39, 40-59, 60-79 and over 80 As regards the infection, the complete course of vaccinations has an efficacy between 79.8% and 81.5%, depending on the age group. For ordinary hospitalizations, the effectiveness ranges from 91.0% to 97.4% with the highest value in the 40-59 year range. For ICU admissions, the efficacy is 100% in the two younger groups (ie there was no ICU admission in the vaccinated in the period considered), and slightly drops to 96.9% in the over 80s. regards deaths, the effectiveness is again 100% in the two younger groups, while it drops to 98.7% in that 60-79 (2 deaths among vaccinated versus 78 of unvaccinated) and 97.2% in the over 80 (15 deaths in vaccinated and 62 in unvaccinated).
Ema also replies to Pfizer: “It is too early to say if and when the third dose will be needed”
The European drug agency Ema also spoke today on Pfizer’s announcement: “It seems that the 4 anti-Covid vaccines authorized in the European Union protect against all strains of Sars-CoV-2 viruses circulating in the EU, including Delta variant. This highlights the importance of a complete vaccination course. It is premature to say if and when the green light for the third dose will be needed “.
Pfizer adapted to the Delta variant
BioNtech and Pfizer have developed an anti Covid-19 vaccine against the Delta variant and want to verify its effectiveness soon. That’s what the manufacturers have announced. The drug adaptation was manufactured in Mainz, and the pharmaceutical company plans to begin testing in August, writes Sueddeutsche Zeitung online. The drug based on messenger Rna (mRna) was adapted and the entire Spike protein with the Delta variant mutations was used.